A Phase I/II Controlled Dose-escalating Trial to Establish the Baseline Safety and Efficacy of a Single Subretinal Injection of rAAV.sFlt-1 Into Eyes of Patients With Exudative Age-related Macular Degeneration (AMD)

Trial Profile

A Phase I/II Controlled Dose-escalating Trial to Establish the Baseline Safety and Efficacy of a Single Subretinal Injection of rAAV.sFlt-1 Into Eyes of Patients With Exudative Age-related Macular Degeneration (AMD)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 May 2017

At a glance

  • Drugs AVA 101 (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Avalanche Biotechnologies
  • Most Recent Events

    • 30 Sep 2015 Results for the phase I portion in 8 patients published online in the Lancet.
    • 15 Jun 2015 Topline results from the phase I and IIa of the study published in an Avalanche Biotechnologies media release.
    • 14 May 2015 Baseline data for the patients from the Phase IIa part of the trial to be presented at the American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top